We have recently found that CP4715, a potent inhibitor against integrin αVβ3, blocks TGF-β signaling, followed by reduced BLM-induced pulmonary fibrosis in mice, suggesting that CP4715 has the potential to be developed as a therapeutic agent for IPF [15]. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.